{"entity":{"id":"nct07736612","kind":"trial","name":"A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","aka":[],"tldr":"A phase 1/2 trial of nimotuzumab, HS-20093 and adebrelimab in pancreatic cancer, run by Zhejiang University, not yet recruiting.","summary":"A Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer is a phase 1/2, interventional study registered as NCT07736612 by Zhejiang University, with a registry enrolment figure of 80 participants, started 2026-08-15 and due to reach its primary completion in 2028-08-30. Interventions recorded: HRS-2329 Tablet; Nimotuzumab; HS-20093; Adebrelimab. Conditions listed: Pancreatic Cancer; RAS Mutations or Amplifications. Primary outcome: Objective Response Rate. Pancreatic eligibility wording from the registry: \"* Histopathologically confirmed locally advanced or metastatic pancreatic adenocarcinoma (originating from pancreatic ductal epithelium) that is not amenable to curative therapy\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07736612","url":"https://clinicaltrials.gov/study/NCT07736612"}],"tags":["ctgov-ingest","pancreatic-deep-dive"],"related":[],"cancers":["locally-advanced-pdac","metastatic-pdac"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["nimotuzumab","hs-20093","adebrelimab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07736612","phase":"1/2","setting":"A Phase Ib/II Study of the Safety, Tolerability, and Efficacy of a Pan-RAS Inhibitor in Combination With Anti-Tumor Therapy in Participants With Advanced Pancreatic Cancer","sponsor":"Zhejiang University","enrolled":80,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07736612/","neighbours":{"cancer":[{"id":"locally-advanced-pdac","kind":"cancer","name":"Locally advanced unresectable pancreatic ductal adenocarcinoma","route":"/cancers/locally-advanced-pdac/"},{"id":"metastatic-pdac","kind":"cancer","name":"Metastatic pancreatic ductal adenocarcinoma","route":"/cancers/metastatic-pdac/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"adebrelimab","kind":"drug","name":"Adebrelimab","route":"/drugs/adebrelimab/"},{"id":"hs-20093","kind":"drug","name":"HS-20093","route":"/drugs/hs-20093/"},{"id":"nimotuzumab","kind":"drug","name":"Nimotuzumab","route":"/drugs/nimotuzumab/"}],"term":[{"id":"pancreatic-trials-open-today","kind":"term","name":"Pancreatic cancer trials open today (registry snapshot and UK sites)","route":"/terms/pancreatic-trials-open-today/"}]}}